Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial
Novartis Pharmaceuticals
Burkert Pieske; Rolf Wachter; Sanjiv J Shah; Abigail Baldridge; Peter Szeczoedy; Ghionul Ibram; Victor Shi; Ziqiang Zhao; Martin R Cowie; PARALLAX Investigators and Committee members